
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries is projected to achieve significant sales growth for its innovative products, with anticipated 2026 revenues of $785 million for Ajovy, reflecting a year-on-year increase of 17%, and $278 million for Uzedy, marking a substantial 45% rise. The company's robust performance is further supported by strong market penetration and projected revenue growth for Austedo, with expectations for peak sales to exceed $3 billion due to an under-treated patient population. Teva's management is also confident in achieving an enhanced EBITDA margin driven by a transition to higher-value products and targeted cost savings of $700 million by 2027, indicating a positive trajectory for both cash flows and overall financial health.
Bears say
Teva Pharmaceutical Industries faces significant challenges that contribute to a negative outlook, highlighted by a sequential decline expected in 1Q26 and anticipated year-over-year declines in 4Q26 due to pricing pressures approaching IRA implementation. The company's fourth-quarter results in 2025 reflected a normalized topline miss, exacerbated by a one-time milestone payment and a decline in generics revenue, which fell short of estimates by 3%, driven by an 11% decrease in US prescriptions. Additionally, risks related to regulatory uncertainty, litigation, and the execution of its pipeline pose potential threats to future financial performance, overshadowing projected debt paydowns and decreases in annual financial expenses.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares